Typically, cyclooxygenases (COXs) and 5-lipoxygenase (5-LOX), enzymes that generate biologically active lipid molecules termed eicosanoids, are considered inflammatory. Hence, their putative role in Alzheimer's disease (AD) has been explored in the framework of possible inflammatory mechanisms of AD pathobiology. More recent data indicate that these enzymes and the biologically active lipid molecules they generate could influence the functioning of the central nervous system and the pathobiology of neurodegenerative disorders such as AD via mechanisms different from classical inflammation. These mechanisms include the cell-specific localization of COXs and 5-LOX in the brain, the type of lipid molecules generated by the activity of these enzymes, the type and the localization of receptors selective for a type of lipid molecule, and the putative interactions of the COXs and 5-LOX pathways with intracellular components relevant for AD such as the gamma-secretase complex. Considering the importance of these multiple and not necessarily inflammatory mechanisms may help us delineate the exact nature of the involvement of the brain COXs and 5-LOX in AD and would reinvigorate the search for novel targets for AD therapy.
Introduction
Recent positron emission tomography (PET) data indicate that the normal human brain consumes 17.8 mg/day of arachidonic acid, and that this consumption increases in the brains of Alzheimer's disease (AD) patients (for review, see Rapoport, 2008) . A portion of intracellular free arachidonic acid is metabolized by cyclooxygenases (e.g., cyclooxygenase-1, COX-1; cyclooxygenase-2, COX-2) and lipoxygenases (e.g., 5-lipoxygenase; 5-LOX) to generate biologically active prostaglandins and leukotrienes, respectively. In the central nervous system (CNS), both COXs and 5-LOX have been associated with pathobiological mechanisms accompanying aging and neurodegeneration (Choi et al., 2009; Chu and Praticò, 2009; Phillis et al., 2006) . A recent study of COX-2 and 5-LOX single nucleotide polymorphisms (SNPs) in AD performed on 341 AD patients and 190 controls from Northern Italy found a significant difference in the distribution of the −765G COX-2 and − 1708A 5-LOX alleles between AD cases and controls -both alleles were overrepresented in AD patients and underrepresented in controls (Listì et al., 2010) . These authors suggested that the identified alleles of COX-2 and 5-LOX could be risk factors for AD.
Since in the periphery, the most prominent function of COXs and 5-LOX is in inflammation, i.e., they are considered "inflammatory" enzymes, findings of the presence and overactivation and overexpression of these enzymes in AD are typically referred to as evidence for an inflammatory basis for AD pathobiology. Furthermore, both COXs and 5-LOX contribute to atherogenesis and it has been proposed that these pathways may be at the core of the comorbidity of cardiovascular and neurological disorders such as AD (Chu and Praticò, 2009; Praticò and Dogné, 2009 ). However, both COX and 5-LOX may influence CNS functioning via mechanisms unrelated to the role these proteins play in inflammation. For example, COX-2, which is predominantly expressed in pyramidal neurons in contrast to COX-1, which is mostly present in microglia, regulates neuroplasticity via its conversion of arachidonic acid to classic prostaglandins but also by favoring oxidative metabolism of endocannabinoids to novel prostaglandins (Yang and Chen, 2008) . On the other hand, 5-LOX appears to be capable of regulating the brain's amyloid-beta levels by influencing gamma-secretase (Firuzi et al., 2008) .
Additional evidence for a putative role of COXs and 5-LOX in AD derives from pharmacological studies using inhibitors of these enzymes (for review, see Firuzi and Praticò, 2006) . In addition to helping delineate the pathobiological mechanisms of AD, these results raise hope for discovering novel therapeutic targets and modalities.
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